Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

• Research collaboration to target severe form of genetic dilated cardiomyopathy
• Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy
• Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ vector biology and manufacturing capacities to deliver its RNA therapies to the heart

Excerpt from the Press Release:

CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.

The strategic collaboration will integrate Solid Biosciences’ vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics. The companies will collaborate to develop novel precision genetic medicines for this form of DCM.

“This collaboration with Phlox Therapeutics is an exciting opportunity to work with a company that shares our commitment and innovative approach to bringing transformative therapies to patients with rare genetic diseases,” said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences.

Click the button below to read the entire Press Release:

Continue Reading The Press Release